Loading...
•
Mar 31, 2022
Organon Q1 2022 Earnings Report
Organon's first quarter results for 2022 showed revenue growth and improved profitability.
Key Takeaways
Organon reported a solid start to the year with a 4% increase in total net revenue, reaching $1,567 million. The company saw growth in Biosimilars and Established Brands, while Women's Health experienced a slight decline. Adjusted EBITDA margin improved to 41.3%.
Total net revenue increased by 4% as-reported and 8% ex-FX compared to Q1 2021.
Women's Health declined 5% as-reported and 3% ex-FX, impacted by Nuvaring and Nexplanon.
Biosimilars revenue grew 22% as-reported and 25% ex-FX, driven by Renflexis and Ontruzant.
Established Brands revenue increased 10% as-reported and 15% ex-FX, benefiting from demand fluctuations and volume growth.
Organon
Organon
Organon Revenue by Segment
Organon Revenue by Geographic Location
Revenue by Segment
Women's Health Revenue
CapyFin.comBiosimilars Revenue
CapyFin.comEstablished Brands Revenue
CapyFin.comOther Revenue
CapyFin.comRevenue by Geographic Location
Europe and Canada Revenue
CapyFin.comUnited States Revenue
CapyFin.comAsia Pacific and Japan Revenue
CapyFin.comChina Revenue
CapyFin.comLatin America, Middle East, Russia, and Africa Revenue
CapyFin.com Forward Guidance
Organon affirmed the full year 2022 financial guidance previously provided on February 17, 2022, which is presented on a non-GAAP basis.
Revenue & Expenses
Visualization of income flow from segment revenue to net income